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DObjectives: The optimal management of mild to moderate functional mitral regurgitation (FMR) during aortic
valve replacement (AVR) for severe aortic insufficiency (AI) is poorly defined. We aimed to investigate the fate
of FMR after AVR with or without concomitant mitral annuloplasty (MAP) and to identify the risk factors and
clinical implications of persistent FMR.
Methods: Between June 1996 and August 2011, 155 patients with mild to moderate FMR undergoing AVR for
severe AI were reviewed. The preoperative MR grade was mild in 101 patients (65%) and moderate in
54 patients (35%). Persistent FMR was defined as MR grade remaining the same or increased on the last
follow-up echocardiogram.
Results: The mean follow-up duration was 4.5  3.9 years. FMR improved in 88% of the patients.
On multivariate analysis, left ventricular end-diastolic dimension (LVEDD) reduction after AVR was identified
as the only predictor for FMR improvement (P¼ .004; hazard ratio, 0.927; confidence interval, 0.881 to 0.977).
Concomitant MAP did not show additional benefit in preventing persistent FMR (P¼ .35). Although no survival
difference was observed between the patients with and without persistent FMR (P ¼ .78), persistent FMR was
associated with greater heart failure events (P<.001).
Conclusions: Mild to moderate FMR as a result of severe AI improved with AVR in most patients with or
without concomitant MAP. Poor postoperative LVEDD reduction was the only risk factor for persistent
FMR. Because persistent FMR tended to be associated with heart failure events, close echocardiographic
monitoring and proactive medical management are recommended in patients showing poor LVEDD reduction
after AVR. (J Thorac Cardiovasc Surg 2014;148:441-6)Functional mitral regurgitation (FMR) is a common finding
in aortic valve disease patients.1,2 However, adequate
guidelines for its management during aortic valve surgery
are lacking.3 Although previous studies have investigated
the fate and clinical impact of mild to moderate FMR in pa-
tients undergoing aortic valve replacement (AVR), they
were mostly conducted mostly in patients with aortic valve
stenosis4-8 and the literature addressing the fate of FMR
specifically in the setting of severe aortic insufficiency
(AI) has been limited. Even less is known about the
outcome and the potential benefits of concomitant mitral
annuloplasty.9 Therefore, we sought to investigate the
following: (1) the fate of mild to moderate FMR aftere Department of Thoracic and Cardiovascular Surgery,a AsanMedical Center,
ersity of Ulsan, College of Medicine, Seoul, Korea; and Department of
cic and Cardiovascular Surgery,b The Catholic University of Korea, Seoul
ary Hospital, Seoul, Korea.
ures: Authors have nothing to disclose with regard to commercial support.
d for publication Jan 3, 2013; revisions received Aug 14, 2013; accepted for
cation Sept 10, 2013; available ahead of print Nov 6, 2013.
for reprints: Suk-Jung Choo, MD, Asan Medical Center, University of Ulsan
ge of Medicine, 388-1 Pungnap-Dong Songpa-Gu, Seoul 138-736,
Korea (E-mail: sjchoo@amc.seoul.kr).
23/$36.00
ht  2014 by The American Association for Thoracic Surgery
.doi.org/10.1016/j.jtcvs.2013.09.030
The Journal of Thoracic and CaAVR for severe AI, (2) the effect of concomitant mitral
annuloplasty (MAP) in the management of mild to
moderate FMR, and (3) the risk factors and clinical implica-
tions of persistent FMR.
PATIENTS AND METHODS
Patients
Between June 1996 and August 2011, 779 patients underwent AVR for
predominantly severe AI. Patients who had trivial (1þ) or severe (4þ)
FMR, MR caused by structurally abnormal mitral valve and subvalvular
apparatus such as rheumatic or degenerative pathology, and ischemic
MR with regional wall motion abnormality were excluded. Based on this
criteria, a total of 155 patients with predominantly severe AI with mild
to moderate functional MR constituted the subject of the present study.
Clinical characteristics and echocardiographic and surgical data were
obtained retrospectively by reviewing the patients’ medical records. The
present study was approved by the Asan Institutional Review Board with
waiver of individual patient consent.
Echocardiographic FMR Grading and Follow-up
Evaluation
Transthoracic and transesophageal echocardiography were performed
preoperatively in all of the patients to assess the etiology and severity of
the MR. FMRwas defined as central MR caused by tethering and fluttering
in the absence of morphologic abnormalities of the mitral leaflets such as
thickening or calcification. Any MRwith regional left ventricular wall mo-
tion abnormality, suggesting an ischemic etiology, also was excluded. MRrdiovascular Surgery c Volume 148, Number 2 441
Abbreviations and Acronyms
AI ¼ aortic insufficiency
AVR ¼ aortic valve replacement
CHF ¼ congestive heart failure
FMR ¼ functional mitral regurgitation
LVEDD ¼ left ventricular end-diastolic dimension
LVESD ¼ left ventricular end-systolic dimension
MAP ¼ mitral annuloplasty
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Dgrade was assessed by measuring the maximum color flow Doppler
regurgitant jet area from the left ventricle to the left atrium during the
systolic phase on a 4-chamber or 2-chamber view. The FMR was graded
as none (0), trivial (1þ), mild (2þ), moderate (3þ), or severe (4þ) on an
ordinal scale. All of the patients had a postoperative transthoracic
echocardiogram before being discharged. Follow-up echocardiography
was performed 6 months or 1 year after surgery in 88% of the patients.
Biannual echocardiographic follow-up evaluation was recommended after
the first year.
Surgical Techniques
Aortic valve replacement was performed by any 1 of 4 surgeons.
Aortobicaval cannulation was used in a routine manner, with institution
of antegrade and retrograde cardioplegia under mild hypothermia. All of
the patients underwent AVRwith either a mechanical or bioprosthetic valve
as appropriate for the patient’s age and clinical condition. Valve size was
determined by intraoperative visual inspection of the aortic annulus and
sizing of the left ventricular outflow tract. During this study period, there
were no specific guidelines available for MAP. As a result, the decision
to perform a concomitant MAP as well as choosing the type of mitral an-
nuloplasty ring was left to the surgeon’s discretion. The determination of
ring sizewas based on the intercommissural distance and the anterior mitral
valve leaflet height.
Follow-up Evaluation
Data collection was performed until October 2011 through interviews
during regular outpatient clinic visits or by telephone inquiry. Follow-up
evaluation was complete in 92% of the patients. Early mortality was
defined as in-hospital death or death within 30 days of surgery. Mortality
was categorized as cardiac or noncardiac based on the contents of the med-
ical records. All deaths were considered to be of cardiac origin unless a
noncardiac origin was established.
The primary study end point was cardiac death. The secondary end
points included changes in the FMR grade after AVR and new-onset
congestive heart failure (CHF) events (death or readmission caused by
CHF) during the follow-up period. FMR was documented as either
improved or persistent. Persistent FMR was defined as an MR grade that
either remained the same or was aggravated in the last echocardiographic
follow-up evaluation from the preoperative finding.Statistical Analysis
Categoric variables are presented as frequencies and percentages,
and continuous variables are expressed as the mean  standard deviation.
Cumulative incidence rates of individual and composite outcomes were
estimated by the Kaplan-Meier method and compared by the log-rank
test. To reduce the impact of treatment selection bias and confounding
potential in this observational study, we performed a rigorous adjustment
for significant differences in patient characteristics by using Cox
proportional-hazards regression models. Results were expressed as hazard
ratios with 95% confidence intervals. All reported P values are 2-sided,442 The Journal of Thoracic and Cardiovascular Surgand P values less than .05 were considered statistically significant. SAS
software version 9.1 (SAS Institute, Inc, Cary, NC) was used for statistical
analysis.RESULTS
Preoperative Characteristics and Surgical Data
The preoperative clinical characteristics are shown in
Table 1. The mean age of the patients was 56  14 years.
Severe AI was the predominant aortic valve pathology in
all of the patients, with only 2 patients showing mixed aortic
valve disease. Grade 2þ FMR was observed in 101 patients
(65%) and grade 3þ FMR was observed in 54 patients
(35%). The mean left ventricular end-systolic dimension
(LVESD) and left ventricular end-diastolic dimension
(LVEDD) were 50.5  11.0 mm and 69.5  9.4 mm,
respectively. MAP was performed in 22 patients (Table
2); preoperative FMR grade was 3þ in 19 patients (86%).
The mean MAP ring size was 30.6  2.9 mm.Clinical Outcomes
Therewere 4 early deaths (2.6%). Twoof themoccurred in
patients who had received concomitant MAP for
preoperative FMR grade 3þ. The mean follow-up duration
was 53.5  47 months. There were 22 late mortalities
(14.2%), of which 3 were caused by cancer-related
complications (1 advanced gastric cancer and 2 lung
cancers). Therefore, the overall cardiac-related mortality
rate was 12.5%. CHF events occurred in 4 patients. Two of
the patients were rehospitalized with aggravated
dyspnea and showed symptomatic improvement with
medical management, but the other 2 patients who had
very low postoperative left ventricular ejection fraction
(ejection fraction, 16%) died of CHF 4 and 9 years
after AVR. There were 7 reoperations during the follow-up
period.Most of the reoperationswere for aortic valve–related
problems such as endocarditis or paravalvular leakage.Changes in Echocardiographic Data After AVR
Postoperative echocardiographic follow-up evaluation
was performed over a mean follow-up duration of 24.3
 11.8 months. The changes in the FMR during the
follow-up period are shown in Figure 1. FMR improved af-
ter aortic valve surgery in 88% (133 of 151) of the patients
and persisted in 12% (18 of 151). When comparing the
FMR from the preoperative state, 84% (83 of 99) of the pa-
tients with grade 2þ FMR and 96% (50 of 52) of the pa-
tients with grade 3þ FMR showed improvement. The
mean LVESD and LVEDD also improved from 50.5 
11.0 mm and 69.5  9.4 mm to 36.3  10.4 mm and
52.4  8.6 mm, respectively. Among the 20 surviving pa-
tients who underwent concomitant MAP, FMR persisted in
1 patient.ery c August 2014
TABLE 1. Patient characteristics
Variables Patients (n ¼ 155) %
Age (y) 56  14
Female sex 50 32
Hypertension 54 35
Diabetes 7 4.5
Coronary artery disease 17 11
Chronic renal failure 3 2
Atrial fibrillation 20 12.9
NYHA functional class
I 40 25.8
II 54 34.8
III 45 29
IV 16 10.3
LVEF (%) 50.2  12.5
LVESD (mm) 50.5  11.0
LVEDD (mm) 69.5  9.4
LA size (mm) 47.3  5.1
RV systolic pressure (mm Hg) 36.5  16.9
Etiology of AI
Degenerative 41 26.4
Root dilatation 34 21.9
Endocarditis 34 21.9
Rheumatic 3 1.9
Others 43 27.7
TR grade
I 75 48.4
II 17 11
III 12 7.7
IV 1 0.6
FMR grade
II 101 65.1
III 54 34.8
NYHA, New York Heart Association; LVEF, left ventricle ejection fraction;
LA, left atrium; RV, right ventricle; TR, tricuspid regurgitation; LVESD, left
ventricular end-systolic dimension; LVEDD, left ventricular end-diastolic dimension;
AI, aortic insufficiency; FMR, functional mitral regurgitation.
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DRisk Analysis for Persistent FMR and Its Clinical
Impact
The patients were divided into 2 groups after AVR
based on the FMR status of their last transthoracic echo-
cardiography (ie, improved [n ¼ 133] and persistentTABLE 2. Surgical data
Concomitant surgery N (%)
Mitral valve repair 22 (14)
Medtronics Duran* 3
St Jude Tailory 4
Carpentier-Edwards Physioz 11
Cosgrove-Edwardsz 4
Tricuspid valve repair 12 (8)
Maze surgery 7 (5)
Ascending aorta replacement 10 (6)
Coronary artery bypass surgery 10 (6)
*Medtronics, Inc, Minneapolis, Minn. ySt Jude Medical, Inc, St Paul, Minn.
zEdwards Lifesciences, Irvine, Calif.
The Journal of Thoracic and CaFMR [n¼ 18]). Preoperative left ventricular ejection frac-
tion was 50.56  12.8 in the improved group and 49.17 
9.3 in the persistent FMR group (P ¼ .58). On univariate
analysis, poor reduction in LVESD, LVEDD, and the pre-
operative left atrium size; presence of chronic renal dis-
ease; and coronary artery disease were risk factors for
persistent postoperative FMR. However, on multivariate
analysis, only poor LVEDD reduction (P ¼ .004; hazard
ratio, 0.927; confidence interval [CI], 0.881 to 0.977)
and preoperative left atrium size (P ¼ .017) were signifi-
cant risk factors for persistent FMR (Table 3). The FMR
type in 71% of the patients (n ¼ 107) was type IIIb, and
was type I in the remaining patients. No significant differ-
ences were observed in the incidence of persistent FMR
between the 2 types of FMR. Concomitant MAP was not
found to be of additional benefit in preventing persistent
FMR. To exclude the influence of MAP from the evalua-
tion, univariate and multivariate analyses were performed
in the patients without MAP, but the results remained
similar to that of the total patient cohort (Table 4).
Persistent FMR did not seem to affect the estimated
long-term survival (P ¼ .709) (Figure 2). However, it is
remarkable that all of the CHF events (n ¼ 4) occurred in
the persistent postoperative FMR patients (P<.001).
DISCUSSION
The present study was focused on assessing the course of
mild to moderate FMR and the clinical impact of persistent
postoperative FMR in patients undergoing AVR for
predominantly severe AI. The results showed FMR
improvement in most of the patients with AVR only. How-
ever, some patients showed persistent FMR, which had an
adverse impact on the clinical outcomes, especially with
respect to a greater incidence of CHF-related events. The
most important factor relating to persistent FMR after
AVR was poorly reduced LVEDD. Concomitant MAP
was not necessarily found to be of greater benefit in prevent-
ing persistent FMR.
Although FMR associated with aortic valve disease is
relatively common, its course may vary depending on the
predominant aortic valve pathology (ie, stenosis or
regurgitation). Although numerous studies were conducted
to define the relationship between FMR and aortic valve
disease, the predominant aortic valve pathology in most
of these studies was aortic stenosis,6,8,10,11 with only a
few of them dealing with predominantly severe AI. Even
in the studies that purportedly investigated mixed aortic
pathologies, the proportion of AI patients was small and
the distinction between the 2 pathologies was unclear.7,12
It is our contention that distinguishing the FMR in
relation to the type of aortic valve pathology is important
because the underlying left ventricular remodeling
behavior may differ accordingly, and thereby affect the
course of the FMR and consequently the overall clinicalrdiovascular Surgery c Volume 148, Number 2 443
FIGURE 1. The changes in the degree of FMR after AVR. FMR, Func-
tional mitral regurgitation; AVR, aortic valve replacement.
TABLE 4. Cox proportional hazards model for predictors of
persistent FMR in patients without concomitant mitral annuloplasty
(n ¼ 131)
Variables
Hazard
ratio
95% confidence
interval P value
Univariate analysis
Age 1.004 0.969 1.041 .807
Sex 1.466 0.544 3.945 .449
Hypertension 0.221 0.028 1.717 .149
Diabetes 2.329 0.293 18.521 .424
NYHA 1.239 0.452 3.397 .677
Coronary artery disease 3.963 1.249 12.578 .019*
Dialysis 9.291 1.074 80.385 .043*
Atrial fibrillation 2.240 0.630 7.964 .213
LVESD difference 0.953 0.903 1.006 .079
LVEDD difference 0.928 0.875 0.984 .013*
LA size 1.136 1.041 1.239 .004*
RV pressure 0.983 0.950 1.017 .315
Tricuspid regurgitation 2.407 0.654 8.857 .186
LVEF 0.968 0.930 1.007 .106
Multivariate analysis
LVEDD difference 0.927 0.749 0.977 .004*
LA size 1.121 1.020 1.231 .017*
NYHA, New York Heart Association; LVESD difference, preoperative LVESD value -
postoperative LVESD value; LVEDD difference, preoperative LVEDD value - postop-
erative LVEDD value; LA, left atrium; RV, right ventricle; LVEF, left ventricle
ejection fraction; LVESD, left ventricular end-systolic dimension; LVEDD, left
ventricular end-diastolic dimension. *P<.05.
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is characterized by ventricular hypertrophy followed by
dilatation as a delayed response to disease progression.
On the other hand, the left ventricular remodeling
response to severe AI is usually dilatation and increase inTABLE 3. Cox proportional hazards model analyzing predictors for
persistent FMR in all patients (n ¼ 151)
Variables
Hazard
ratio
95% confidence
interval P value
Univariate analysis
Age 1.003 0.969 1.038 .859
Sex 1.531 0.588 3.987 .383
Hypertension 0.455 0.100 2.068 .308
Diabetes 2.699 0.339 21.467 .348
NYHA 0.981 0.365 2.636 .969
Coronary artery disease 3.352 1.178 9.543 .023*
Dialysis 10.703 1.237 92.623 .031*
Atrial fibrillation 2.333 0.748 7.275 .144
LVESD difference 0.944 0.897 0.993 .026*
LVEDD difference 0.923 0.877 0.972 .002*
LA size 1.074 1.000 1.153 .051
RV pressure 0.977 0.943 1.012 .189
Tricuspid regurgitation 1.870 0.525 6.660 .334
Mitral annuloplasty 0.381 0.050 2.884 .350
LVEF 0.974 0.938 1.011 .167
Multivariate analysis
LVEDD difference 0.927 0.881 0.977 .004*
NYHA, New York Heart Association; LVESD difference, preoperative LVESD value -
postoperative LVESD value; LVEDD difference, preoperative LVEDD value - post-
operative LVEDD value; LVESD, left ventricular end-systolic dimension;
LVEDD, left ventricular end-diastolic dimension; LA, left atrium; RV, right ventricle;
LVEF, left ventricle ejection fraction. *P<.05.
444 The Journal of Thoracic and Cardiovascular SurgLV mass. Therefore, the onset and LV dysfunctional state
secondary to myocardial remodeling in patients with
predominantly severe AI may be qualitatively different
from aortic stenosis. From this perspective, the presentFIGURE 2. Freedom from cardiac mortality. FMR, Functional mitral
regurgitation.
ery c August 2014
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remodeling and FMR in AVR patients with predominantly
severe AI. The reversal of FMR after AVR in these
patients was rapid with significant reverse remodeling that
was characterized by decreased LVEDD and FMR
improvement within the first few months of surgery.
Although the findings of this study may guide proactive
postoperative medical treatment in those patients showing
poor LVEDD reduction, the surgical utility remains
limited because significant preoperative factors predicting
persistent postoperative FMR were not identified.
Until recently, most studies on FMR involved patients
with MR ranging between 1þ or 2þ.7,9,12,13 In this
study, we chose to limit our patients to those with MR
grade 2þ or 3þ MR because the treatment of FMR in this
group of patients remains the most controversial. A total
of 35% of the patients had grade 3þ FMR and,
remarkably, most of them (96%) showed improvement in
their MR after AVR alone without concomitant MAP.
Therefore, the results seemed to suggest that AVR alone
may be sufficient to induce the necessary reverse
remodeling for correcting the mild to moderate FMR, but
the relatively small population of 155 patients in the
present study warrants further investigation over a larger
cohort and longer duration to adequately assess the
clinical implications.
Although it is intuitive to expect a greater preventive
effect on persistent postoperative FMR by concomitant
MAP, multivariate analysis showed no additional benefit
with MAP, even in patients with preoperative grade
3þ MR. These findings corroborate the views argued by
Wan et al9 that AVR alone in most cases is highly effective
in resolving mild to moderate FMR at the time of AVR. In a
review by Abdullah et al,5 the cause of MR worsening after
AVR was suggested to be multifactorial.10,12,14-16 In the
present study, poor reduction in LVEDD was the only
significant risk factor identified for persistent FMR after
AVR (P¼ .004). Joo et al7 also suggested LVEDD increase
to be predictive of persistent FMR on univariate analysis.
These findings stress the significant role of adverse LV re-
modeling in contributing to persistent FMR after AVR.
Although the size of the preoperative LVEDDwas not a sig-
nificant predictor of persistent FMR, changes in LVEDD
(ie, poorly reduced LVEDD after AVR) were identified as
having an adverse influence on the clinical outcomes, veri-
fying the importance of the postoperative LV remodeling
behavior. The clinical impact of persistent FMR was most
readily apparent through its greater association with
increased CHF events during the follow-up period. This
was consistent with the reported long-term outcomes of pre-
vious studies that showed an increased incidence of CHF-
related events in patients with persistent FMR.6,12 The
tendency for a decrease in the LVEDD to be associated
with greater FMR improvement as observed in the presentThe Journal of Thoracic and Castudy is consistent with the outcomes reported by Ruel
et al.12Study Limitations
Limitations include the retrospective nature of the
present study and the possibility of treatment bias by the
attending surgeons. The relatively short follow-up duration
and the small number of CHF events are further limitations.
Although the relatively homogenous study population con-
sisting of patients with predominantly severe AI adds sup-
port to the arguments advocated in the present study,
further long-term studies in a larger study cohort are war-
ranted to identify the preoperative risk factors of persistent
postoperative FMR and the surgical utility of the present
study findings.CONCLUSIONS
Mild to moderate FMR associated with severe AI showed
improvement after aortic valve surgery alone in most pa-
tients. Concomitant MAP did not result in an additional
beneficial effect in preventing persistent FMR. The
only risk factor for persistent FMR after AVR was
poor LVEDD reduction on follow-up echocardiography.
Although persistent FMR did not affect the overall survival
rate, it tended to be associated with a higher incidence of
congestive heart failure events during the follow-up
period. Therefore, proactive medical management is
recommended in patients with poor LVEDD reduction after
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